Newspaper Publication for declaration of Annual Financial Results (Consolidated and Standalone) for the quarter and financial year ended March 31, 2026.
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mangalam Drugs & Organics Ltd published its audited financial results for Q4 and FY26. Total income from operations stood at ₹7,737.65 lakh in Q4 and ₹23,289.58 lakh for the full year. The company incurred a net loss of ₹1,306.04 lakh in Q4 (vs. profit of ₹15.09 lakh in Q4 FY25) and a net loss of ₹4,381.42 lakh for FY26 (vs. profit of ₹682.43 lakh in FY25). This represents a dramatic year-over-year deterioration, with the company turning loss-making due to declining revenue and likely increased expenses. Basic EPS for FY26 was ₹-27.68 per share, a sharp decline from ₹4.37 in FY25. The Board approved the results on May 14, 2026.
The company swung to significant losses in FY26, which is a major concern for shareholders. The stock may face selling pressure as the financial performance is substantially worse than the prior year.